Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neena Brizmohun

Neena Brizmohun writes and commissions news, features and analysis to meet the regulatory, business and market access information needs of the companies and regulatory agencies that operate in the pharmaceutical and medical device space worldwide.

Her areas of expertise include the cutting-edge early market access schemes that are being trialed around the world for taking drugs and medical devices to market faster. She is also interested in initiatives for harmonizing regulations at the global level as well as issues affecting clinical trials, manufacturing and post-market safety monitoring. She explores the challenges and opportunities that these issues introduce for both industry and the regulators and is on a constant look out for what might be coming next.

A scientist by training, Neena started her journalistic career at Informa in 1997. She has been the deputy editor of Scrip Regulatory Affairs since 2007. Prior to that, she worked as the science editor for Clinica Medtech Intelligence. Before becoming a journalist she worked as a biomedical scientist at St Thomas' Hospital in London for 10 years.
Advertisement
Set Alert for Articles By Neena Brizmohun

Latest From Neena Brizmohun

Pharma Fees To Soar In Canada Under Government Proposals

The licence evaluation fee Health Canada charges for drugs containing new active substances could jump by 76% under proposals by the government department, which says its current fees for pharma and medtech are outdated and need to change.

Drug Review Regulation

Medtech Fees To Soar In Canada Under Government Proposals

The licence evaluation fee Health Canada charges for Class IV medical devices could jump from CAN$12,347-$22,560 to $30,063 under proposals by the government agency, which says the current fees it charges for medtech and pharma are outdated.

Approvals Canada

Australian Black Triangle Scheme To Start in 2018

From next year drug manufacturers operating in Australia will have to start placing a black triangle symbol on the product information and consumer medicines information documents for certain newly approved prescription products and new indications.

Australia Drug Safety

Pharma Urged To Comply With New EU Excipient Labeling Requirements

Drug labels must be updated to factor in new safety advice on excipients, the European Medicines Agency says.

Europe Regulation

Cinfa Banks On ‘Multi-Layered’ Scientific Advice As It Files For EU Pegfilgrastim Biosimilar Review

Cinfa Biotech is hoping that the advice it received from the EU regulators during the development of its pegfilgrastim biosimilar will help it succeed where others have failed.

Biosimilars Drug Review

European Commission Gives Sneak Preview Of Hotly-Awaited Pediatrics Report

The European Commission’s soon-to-be-published report on the EU Paediatric Regulation could lead to legislative changes that address some of the many problems pharma companies have with the 10-year old rules.

Pediatrics Europe
See All
Advertisement
UsernamePublicRestriction

Register